Pembrolizumab-Induced Adrenal Insufficiency in Patients with Untreated Advanced Non-Small Cell Lung Cancer : A Case Series
Copyright © 2021 by S. Karger AG, Basel..
Pembrolizumab-induced adrenal insufficiency (AI) is recognized as a rare immune-related adverse event (irAE) that can be fatal if diagnosis is delayed. Clinical features of AI in patients with advanced non-small cell lung cancer (NSCLC) who received pembrolizumab as the first-line treatment were observed. Five out of 49 patients with untreated advanced NSCLC developed AI between April 2017 and February 2021. Of the 5 patients, 4 developed AI with a grade >3 and were hospitalized. The median time of the onset of AI from the start of first-line treatment was 4.63 months. All the patients improved after corticosteroid replacement therapy. The efficacy of treatment was complete response in 1 patient and partial response in 4 patients. Median progression-free survival was 37.7 months, and overall survival had not been reached. This case series revealed the efficacy of immunotherapy in AI as an irAE.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Case reports in oncology - 14(2021), 3 vom: 15. Sept., Seite 1561-1566 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sonehara, Kei [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adrenal insufficiency |
|---|
| Anmerkungen: |
Date Revised 25.12.2021 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1159/000519597 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM334858992 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM334858992 | ||
| 003 | DE-627 | ||
| 005 | 20231225224614.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1159/000519597 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1116.xml |
| 035 | |a (DE-627)NLM334858992 | ||
| 035 | |a (NLM)34949996 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sonehara, Kei |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pembrolizumab-Induced Adrenal Insufficiency in Patients with Untreated Advanced Non-Small Cell Lung Cancer |b A Case Series |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 25.12.2021 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2021 by S. Karger AG, Basel. | ||
| 520 | |a Pembrolizumab-induced adrenal insufficiency (AI) is recognized as a rare immune-related adverse event (irAE) that can be fatal if diagnosis is delayed. Clinical features of AI in patients with advanced non-small cell lung cancer (NSCLC) who received pembrolizumab as the first-line treatment were observed. Five out of 49 patients with untreated advanced NSCLC developed AI between April 2017 and February 2021. Of the 5 patients, 4 developed AI with a grade >3 and were hospitalized. The median time of the onset of AI from the start of first-line treatment was 4.63 months. All the patients improved after corticosteroid replacement therapy. The efficacy of treatment was complete response in 1 patient and partial response in 4 patients. Median progression-free survival was 37.7 months, and overall survival had not been reached. This case series revealed the efficacy of immunotherapy in AI as an irAE | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Adrenal insufficiency | |
| 650 | 4 | |a Immune-related adverse events | |
| 650 | 4 | |a Non-small cell lung cancer | |
| 650 | 4 | |a Pembrolizumab | |
| 700 | 1 | |a Tateishi, Kazunari |e verfasserin |4 aut | |
| 700 | 1 | |a Araki, Taisuke |e verfasserin |4 aut | |
| 700 | 1 | |a Komatsu, Masamichi |e verfasserin |4 aut | |
| 700 | 1 | |a Akahane, Jumpei |e verfasserin |4 aut | |
| 700 | 1 | |a Yamamoto, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Hanaoka, Masayuki |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Case reports in oncology |d 2008 |g 14(2021), 3 vom: 15. Sept., Seite 1561-1566 |w (DE-627)NLM195637992 |x 1662-6575 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2021 |g number:3 |g day:15 |g month:09 |g pages:1561-1566 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1159/000519597 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2021 |e 3 |b 15 |c 09 |h 1561-1566 | ||